Kidney function on admission predicts in-hospital mortality in COVID-19

  1. Sinan Trabulus
  2. Cebrail Karaca
  3. Ilker Inanc Balkan
  4. Mevlut Tamer Dincer
  5. Ahmet Murt
  6. Seyda Gul Ozcan
  7. Rıdvan Karaali
  8. Bilgul Mete
  9. Alev Bakir
  10. Mert Ahmet Kuskucu
  11. Mehmet Riza Altiparmak
  12. Fehmi Tabak
  13. Nurhan Seyahi

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1371/journal.pone.0238680
  2. ScreenIT

    SciScore for 10.1101/2020.06.18.20134627: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study protocol was approved by the local medical ethical committee (approval no: 2020-56318) and the Scientific Committee of the Ministry of Health (approval no: 2020-05-07T13_09_11).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    All tests were performed using SPSS for Windows, version 22.0 software (SPSS Inc, Chicago, IL, USA).
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    There are several limitations of our paper. First, urine analysis was not available in a large proportion of patients and we did not collect data on kidney imaging. Therefore, we might have overlooked some patients with CKD. Second, our follow-up duration was limited by the hospital stay period of the patients. The recovery patterns of kidney function might change during a longer follow-up. Third, we did not perform a formal power analysis to determine the sample size, however, we recruited all eligible patients that were hospitalized. Fourth, our study was performed in a leading university hospital, it is possible that we might have recruited more severe patients. Finally, the generalizability of our results to other countries might be limited since countries have adopted different treatment guidelines according to local regulations and the availability of health resources. In conclusion, eGFR on admission seems to be a prognostic marker for mortality in patients with COVID-19. We recommend that eGFR should be determined in all patients on admission and used as an additional tool for risk stratification. Close follow-up might be warranted in patients with a reduced eGFR.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.06.18.20134627v1 on medRxiv